ArticleJournal of thoracic disease2025
The impact of preoperative percutaneous transthoracic needle biopsy on pleural recurrence in clinically early-stage non-small cell lung cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The potential association between preoperative percutaneous transthoracic needle biopsy (PTNB) and pleural recurrence in lung cancer remains controversial. This study aimed to determine whether PTNB increases the risk of pleural recurrence in patients with clinically diagnosed stage I non-small cell lung cancer (NSCLC). Methods: We retrospectively analyzed 1,733 patients with clinical stage I NSCLC who underwent surgical resection between January 2018 and December 2020. Patients were divided into the PTNB group (n=699) and the non-PTNB group (n=1,034). After 1:1 propensity score matching (PSM), risk factors for pleural recurrence were assessed using Fine-Gray subdistribution hazard models. Cumulative incidence rate and overall survival (OS) were also analyzed. Results: After matching, 530 patients were included in each group. Multivariate Fine-Gray analysis revealed that PTNB [subdistribution hazard ratio (sHR) =3.74; 95% confidence interval (CI): 1.06-13.20; P=0.040] and visceral pleural invasion (VPI) (sHR =3.12; 95% CI: 1.10-8.90; P=0.03) were independent risk factors for isolated pleural recurrence, whereas lymphatic invasion was not (sHR =2.32; 95% CI: 0.82-6.56; P=0.11). For all types of recurrence, PTNB, VPI, and lymphatic invasion were significant predictors (all P<0.05). A subgroup analysis was conducted in patients without VPI or lymphatic invasion (n=1,142; PTNB group =332, non-PTNB group =810), representing a low-risk cohort for pleural recurrence. After PSM, 320 patients were included in each group with well-balanced baseline characteristics. In this subgroup, PTNB remained a significant risk factor for isolated pleural recurrence in the univariate Fine-Gray analysis (sHR =2.29; 95% CI: 1.19-4.38; P=0.01) and for all recurrence types (sHR =2.13; 95% CI: 1.13-4.01; P=0.01). Pathologic tumor size was also consistently associated with increased recurrence risk. In multivariate models PTNB, non-adenocarcinoma histology, and larger pathological tumor size were associated with both isolated pleural and overall recurrence (all P<0.001). Conclusions: Preoperative PTNB was statistically correlated with an increased pleural recurrence in clinical stage I NSCLC, even among patients without conventional high-risk pathological features. Careful consideration is warranted when deciding on PTNB for early-stage disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.